VALVES AND INTRA-ATRIAL SHUNTS AND HEART FAILURE

Sunday, March 8, 2026

11:22 AM - 12:33 PM EST

Location: Georgetown

Moderator(s)

JoAnn Lindenfeld, MD

Director, Heart Failure and Transplantation
Vanderbilt University
Nashville, Tennessee, United States

Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AbioMed: Consulting Fees (e.g., advisory boards) (Ongoing); Alleviant Medical: Consulting Fees (e.g., advisory boards) (Ongoing); AskBio: Consulting Fees (e.g., advisory boards) (Ongoing); Axon: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Cordio: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Intershunt,: Consulting Fees (e.g., advisory boards) (Ongoing); Kestra: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious: Consulting Fees (e.g., advisory boards) (Ongoing); Volumetrix: Consulting Fees (e.g., advisory boards) (Ongoing); VWave: Consulting Fees (e.g., advisory boards) (Ongoing); Whiteswell: Consulting Fees (e.g., advisory boards) (Ongoing)
Chaim Shaul Lotan, MD

Chief Innovation Officer
Hadassah-Hebrew University Medical Center
Jerusalem, Israel

Disclosure(s): No financial relationships to disclose
James Udelson, MD

Chief, Division of Cardiology
Tufts Medical Center
Boston, Massachusetts, United States

Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Disclosure(s):

JoAnn Lindenfeld, MD: Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AbioMed: Consulting Fees (e.g., advisory boards) (Ongoing); Alleviant Medical: Consulting Fees (e.g., advisory boards) (Ongoing); AskBio: Consulting Fees (e.g., advisory boards) (Ongoing); Axon: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Cordio: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Intershunt,: Consulting Fees (e.g., advisory boards) (Ongoing); Kestra: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious: Consulting Fees (e.g., advisory boards) (Ongoing); Volumetrix: Consulting Fees (e.g., advisory boards) (Ongoing); VWave: Consulting Fees (e.g., advisory boards) (Ongoing); Whiteswell: Consulting Fees (e.g., advisory boards) (Ongoing)

Chaim Shaul Lotan, MD: No financial relationships to disclose

James Udelson, MD: Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)